Showing 5461-5470 of 7710 results for "".
- NPF and Boehringer Unite to Launch First GPP Awareness Dayhttps://practicaldermatology.com/news/NPF-Boehringer-Unite-Launch-First-GPP-Awareness-Day/2475890/Key Takeaways NPF and Boehringer Ingelheim launched a campaign to educate and support individuals with generalized pustular psoriasis.
- Analysis: Arnica’s Popularity on Social Not Supported by Data for Post-Procedure Recoveryhttps://practicaldermatology.com/news/analysis-arnicas-popularity-on-social-media-outpaces-scientific-support-for-post-procedure-recovery/2475830/Social media users and health care professionals frequently endorse Arnica montana for reducing bruising and swelling following aesthetic injectables, but a recent analysis shows scientific support for its use may be lacking.
- Multimodal "Toolkit" Enhances AI Detection of Skin Lesions: Researchershttps://practicaldermatology.com/news/multimodal-dataset-enhances-ai-detection-of-skin-lesions/2475786/A new open-access dataset, MILK10k, provides over 10,000 multimodal images to improve machine learning performance in the diagnosis of both pigmented and non-pigmented skin cancers and simulators. According to researchers publ
- Study: Frequent AD Flares Forecast Worse Outcomes in Following Yearhttps://practicaldermatology.com/news/study-frequent-ad-flares-forecast-worse-outcomes-in-following-year/2475765/Frequent flares of atopic dermatitis (AD) are predictive of worse disease severity and reduced quality of life, according to findings from a large cohort study. Researchers for the study examined data from the Danish Skin Coho
- LEQSELVI™ Launches in U.S. as Oral Treatment for Severe Alopecia Areatahttps://practicaldermatology.com/news/leqselvitm-launches-in-us-as-oral-treatment-for-severe-alopecia-areata/2475680/Sun Pharmaceutical Industries Ltd. announced the U.S. commercial availability of LEQSELVI™ (deuruxolitinib), an oral Janus kinase (JAK) inhibitor indicated for the treatment of adults with severe alopecia areata, according to a press release from the manufacturer.
- Positive Early Results in Tralokinumab Trial for AD on Handshttps://practicaldermatology.com/news/Positive-Early-Results-Tralokinumab-Trial-AD-Hands/2475575/A trial evaluating tralokinumab for the treatment of adults with moderate-to-severe atopic dermatitis (AD) on the hands, who are candidates for systemic therapy, met the primary endpoint and all secondary endpoints with a statistically significant improvement in AD on the hands after 16 weeks of
- Study: Iron Oxide Formulation Improved Radiance in Melasma-Prone Skinhttps://practicaldermatology.com/news/study-feo-formulation-improves-radiance-in-melasma-prone-skin/2475517/A new study published in Journal of Drugs in Dermatology evaluated the incorporation of iron oxide (FeO) into a daily sun care routine could offer protection and any benefit for patients with melasma and photodamage.
- Study: 90% Would Purchase Red Light Therapy Deviceshttps://practicaldermatology.com/news/study-90-would-purchase-red-light-therapy-devices/2475498/New research published in the Journal of Clinical and Aesthetic Dermatology showed how social media is fueling the growing consumer demand for over-the-counter (OTC) red light therapy (RLT) devices. The authors of the
- Study: Sofpironium Gel Effective for Axillary Hyperhidrosishttps://practicaldermatology.com/news/phase-3-data-support-sofpironium-gel-for-axillary-hyperhidrosis/2475489/Sofpironium topical gel, 12.45%, showed efficacy and tolerability in treating primary axillary hyperhidrosis, according to pooled results from two pivotal Phase 3 trials. Researchers for the combined analysis of the Cardigan
- VISIBLE: Guselkumab Provides Scalp Psoriasis Relief in Diverse Skin Toneshttps://practicaldermatology.com/news/visible-guselkumab-provides-scalp-psoriasis-relief-in-diverse-skin-tones/2475455/Guselkumab 100 mg demonstrated efficacy and sustained improvement through 48 weeks in a cohort of adults with moderate to severe scalp psoriasis and skin of color, new research suggests. In the B cohort of the phase 3b, rand